A phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 In Combination with either anastrozole or letrozole versus exemestane alone in ER positive breast cancer patients who are progressing on current treatment with Anastrozole or Letrozole

Trial Profile

A phase IIa study (with combination safety run-in) to assess the safety and efficacy of AZD4547 In Combination with either anastrozole or letrozole versus exemestane alone in ER positive breast cancer patients who are progressing on current treatment with Anastrozole or Letrozole

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs AZD 4547 (Primary) ; Anastrozole; Exemestane; Letrozole
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RADICAL
  • Most Recent Events

    • 17 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 04 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top